SequelSEC

10x Genomics, Inc. TXG

Laboratory Analytical Instruments · CIK 0001770787 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$616.91M
Fiscal year ended 2026-06-30
Operating income
-$88.38M
Fiscal year ended 2026-06-30
Free cash flow
$121.44M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$1.30BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float / revenue2.0×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.6×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Laboratory Analytical Instruments filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.9%0th
Gross margin69.1%100th
FCF margin20.2%89th
SBC / revenue17.0%75th
Operating margin-9.5%60th
Net margin-6.8%59th
Revenue YoY growth5.2%59th
Current ratio4.46x57th

10x Genomics, Inc. (TXG) reported revenue of $616.91M and net income of -$75.12M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from 10x Genomics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Laboratory Analytical Instruments.

Income

10x Genomics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$616.91M
Cost of revenue$184.88M
Gross profit$432.03M
Operating income-$88.38M
Net income-$75.12M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$74.89M
Income tax expense$235.00K
Diluted EPSUnavailable
Selling, general & administrative$297.01M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

10x Genomics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalentsUnavailable
Total assets$1.03B
Current assets$674.67M
Total liabilities$204.52M
Current liabilities$118.51M
Total equity incl. NCI$825.55M
Temporary (mezzanine) equityUnavailable
Inventory$52.62M
Accounts receivable$47.54M
Goodwill$6.92M
Long-term debtUnavailable
Accounts payable$20.69M

Cash flow

10x Genomics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$127.08M
Capital expenditures$5.65M
Investing cash flow-$19.65M
Financing cash flow-$2.54M
Net change in cash$104.80M
Stock-based compensation$98.74M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$39.98M

Derived

10x Genomics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$121.44M
Gross margin70.0%
Operating margin-14.3%
FCF margin19.7%
SBC / revenue16.0%
Current ratio5.69x
Revenue YoY growth-4.3%
Net margin-12.2%
R&D / revenueUnavailable
CapEx / revenue0.9%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TXG in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-02-13View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

A ASTC AVTR BFNH BIO BNGO BRKR CTKB EYPT HBIO ILMN LCTC

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.